antifolate chemotherapy

antifolate chemotherapy

Antifolate therapy Oncology The use of an antimetabolite–eg, MTX, to compete with folate, inhibiting dihydrofolate reductase, the enzyme responsible for → inactive dihydrofolate into an active tetrahydrofolate; this block causes a buildup of toxic dihydrofolate, shutting down synthesis of purine nucleotides and thymidylate; AC is used to treat malignancy. See Leukovorin rescue. Methotrexatre
Mentioned in ?
References in periodicals archive ?
The reason patients with the MTHFR gene mutation suffer more severe side effects of antifolate chemotherapy, Ulrich hypothesizes, is because their bodies lack the adequate folate necessary to produce nucleotides -- a key component of the DNA-repair machinery.